Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: Analysis of 1,110 cases

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhang, Jing ^a   Zheng, Jianming ^b   Yang, Yinghong ^c   Lu, Junliang ^a   Gao, Jie ^a   Lu, Tao ^a   Sun, Jian ^a   Jiang, Hui ^b   Zhu, Yan ^b   Zheng, Yuhui ^c   Liang, Zhiyong ^a   Liu, Tonghua ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL TUMOR; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; FEMALE; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); YOUNG ADULT;

EID: 84951828257     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18678     Document Type: Article

References (48)

1. Zheng, Z. X., Zheng, R. S., Zhang, S. W. & Chen, W. Q. Colorectal cancer incidence and mortality in china, 2010. Asian Pac J Cancer Prev 15, 8455-8460 (2014).
2. Arnold, D. & Schmoll, H. J. Colorectal cancer: (neo-) adjuvant treatments in colorectal cancer. Ann Oncol 16, 133-140 (2005).
3. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9, 550-562 (2009).
4. Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573 (2005).
5. McCubrey, J. A. et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46, 249-279 (2006).
6. Calistri, D. et al. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 204, 484-488 (2005).
7. Wilson, P. M., Labonte, M. J. & Lenz, H. J. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J 16, 262-272 (2010).
8. Allegra, C. J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27, 2091-2096 (2009).
9. Sartore-Bianchi, A. et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4, e7287 (2009).
10. Laurent-Puig, P. et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27, 5924-5930 (2009).
11. De Roock, W., Lambrechts, D. & Tejpar, S. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 360, 834 (2009).
12. De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11, 753-762 (2010).
13. Shen, Y. et al. Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One 8, e81628 (2013).
14. Smith, C. G. et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy cetuximab. Clin Cancer Res 19, 4104-4113 (2013).
15. Peyssonnaux, C. & Eychene, A. The Raf/MEK//ERK pathway: new concepts of activation. Biol Cell 93, 53-62 (2001).
16. Harari, P. M., Allen, G. W. & Bonner, J. A. Biology of interactions: anti-epidermal growth factor receptor agents. J Clin Oncol 25, 4057-4065 (2007).
17. Bonomi, P. D., Buckingham, L. & Coon, J. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 13, s4606-s4612 (2007).
18. Linardou, H. et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9, 962-972 (2008).
19. Dassonville, O., Bozec, A., Fischel, J. L. & Milano, G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 62, 53-61 (2007).
20. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626-1634 (2008).
21. De Roock, W. et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19, 508-515 (2008).
22. Mao, C. et al. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One 7, e36653 (2012).
23. Berg, M. et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CAPTEN-TP53 related to age at disease onset. PLoS One 5, e13978 (2010).
24. Ling, Y. et al. Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma. Zhonghua Bing Li Xue Za Zhi 41, 590-594 (2012).
25. Hsieh, L. L. et al. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta 413, 1605-1611 (2012).
26. Bando, H. et al. Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. BMC Cancer 13, 405 (2013).
27. Soeda, H. et al. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol 18, 670-677 (2013).
28. Bagadi, S. B., Sanghvi, M., Nair, S. B. & Das, B. R. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers 27, 27-33 (2012).
29. Bisht, S., Ahmad, F., Sawaimoon, S., Bhatia, S. & Das, B. R. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution patternin Indian colorectal carcinoma. Med Oncol 31, 124 (2014).
30. Simi, L. et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130, 247-253 (2008).
31. Cappuzzo, F. et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 99, 83-89 (2008).
32. Ogino, S. et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27, 1477-1484 (2009).
33. Baldus, S. E. et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16, 790-799 (2010).
34. Lurkin, I. et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 5, e8802 (2010).
35. Liao, X. et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367, 1596-1606 (2012).
36. Guedes, J. G. et al. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wildtype metastatic colorectal cancer. BMC Cancer 13, 169 (2013).
37. Balschun, K. et al. KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. J Mol Diagn 13, 436-445 (2011).
38. Therkildsen, C., Bergmann, T. K., Henrichsen-Schnack, T., Ladelund, S. & Nilbert, M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 53, 852-864 (2014).
39. Neumann, J., Zeindl-Eberhart, E., Kirchner, T. & Jung, A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205, 858-862 (2009).
40. Benvenuti, S. et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67, 2643-2648 (2007).
41. Tran, B. et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117, 4623-4632 (2011).
42. Yokota, T. et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104, 856-862 (2011).
43. Gonsalves, W. I. et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.3. J Natl Cancer Inst 106 (2014).
44. Mao, C., Yang, Z. Y., Hu, X. F., Chen, Q. & Tang, J. L. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 23, 1518-1525 (2012).
45. Janku, F. et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6, e22769 (2011).
46. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3, 11-22 (2003).
47. Irahara, N. et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 19, 157-163 (2010).
48. Negru, S. et al. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open 23, e004652 (2014).